Pro Medicus Ltd (ASX: PME) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Pro Medicus Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $13.33 billion
P/E Ratio 48.23
Dividend Yield 0.51%
Shares Outstanding 104.47 million
Earnings per share 2.243
Dividend per share 0.64
Year To Date Return -47.80%
Earnings Yield 2.07%
Franking 100%
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Pro Medicus Ltd (ASX: PME)
    Latest News

    A group of young people celebrate and party outside.
    Best Shares

    Top ASX shares to buy in January 2025

    Popping the cork on some new ASX shares in January?

    Read more »

    Young man with a laptop in hand watching stocks and trends on a digital chart.
    Share Market News

    ASX shares in 2024: A year in review

    As we move into 2025, now would be a good time to reflect on the year that was for ASX…

    Read more »

    Six smiling health workers pose for a selfie.
    Healthcare Shares

    Are CSL and this ASX 200 healthcare stock buys in January?

    Is now a good time to pick up these shares? Let's see what analysts are saying.

    Read more »

    Researchers and doctors with futuristic 3d hologram overlay for body anatomy or dna in hospital clinic.
    Share Market News

    Guess which ASX 200 tech stock is rising on $30m contract win

    Another contract win has been announced by this high-flying stock. Let's dig deeper into it.

    Read more »

    Ecstatic woman looking at her phone outside with her fist pumped.
    Broker Notes

    Why Goldman Sachs is bullish on these ASX 200 shares

    Let's see what the broker is saying about these shares right now.

    Read more »

    Three business people look stressed as they contemplate stacks of extra paperwork.
    Growth Shares

    These ASX 200 shares could be buys if there's a stock market crash in 2025

    Analysts have buy ratings on these shares. Here's why they could be great options in the event of a market…

    Read more »

    Hand holding Australian dollar (AUD) bills, symbolising ex dividend day. Passive income.
    Broker Notes

    Invest $1,000 into Pilbara Minerals and these ASX 200 stocks

    Analysts have named these shares as top picks for a $1,000 investment. Let's see why.

    Read more »

    A happy man and woman on a computer at Christmas, indicating a positive trend for retail shares.
    Opinions

    2 ASX 200 shares I'd want to receive as a present today

    Merry Christmas! Are there any stocks under your tree?

    Read more »

    Man drawing an upward line on a bar graph symbolising a rising share price.
    Share Gainers

    Why EOS, News Corp, Polynovo, and Pro Medicus shares are roaring higher today

    These shares are starting the week positively. But why?

    Read more »

    A young man working from home sits at his home office desk holding a cup of tea and looking out the window
    Technology Shares

    Pro Medicus shares higher on $30m contract win

    Good news is lifting this high-flying stock on Monday. Let's dig deeper into it.

    Read more »

    Hands reaching high for a trophy with a sunset in the background.
    How to invest

    I'm taking Warren Buffett's advice for when ASX shares are at record highs

    Would the Oracle of Omaha continue to buy shares when the market is at a record high?

    Read more »

    a man sits at his desk wearing a business shirt and tie and has a hearty laugh at something on his mobile phone.
    Broker Notes

    Top brokers name 3 ASX shares to buy next week

    Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

    Read more »

    Frequently Asked Questions

    Yes, the company historically pays two fully franked dividends a year. 

    Pro Medicus generally pays its shareholder dividends in March and October.

    Pro Medicus Ltd listed on the ASX on 10 October 2000.

    Dividend Payment History Data provided by Morningstar.

    Data provided by Morningstar.
    Ex-Date Amount Franking Type Payable
    03 Sep 2025 $0.3000 100.00% Final 25 Sep 2025
    27 Feb 2025 $0.2500 100.00% Interim 21 Mar 2025
    04 Sep 2024 $0.2200 100.00% Final 26 Sep 2024
    29 Feb 2024 $0.1800 100.00% Interim 22 Mar 2024
    06 Sep 2023 $0.1700 100.00% Final 28 Sep 2023
    02 Mar 2023 $0.1300 100.00% Interim 24 Mar 2023
    08 Sep 2022 $0.1200 100.00% Final 30 Sep 2022
    03 Mar 2022 $0.1000 100.00% Interim 25 Mar 2022
    09 Sep 2021 $0.0800 100.00% Final 01 Oct 2021
    04 Mar 2021 $0.0700 100.00% Interim 19 Mar 2021
    10 Sep 2020 $0.0600 100.00% Final 02 Oct 2020
    05 Mar 2020 $0.0600 100.00% Interim 20 Mar 2020
    12 Sep 2019 $0.0450 100.00% Final 04 Oct 2019
    12 Mar 2019 $0.0250 100.00% Special Cash 17 May 2019
    07 Mar 2019 $0.0350 100.00% Interim 22 Mar 2019
    06 Sep 2018 $0.0350 100.00% Final 27 Sep 2018
    08 Mar 2018 $0.0250 100.00% Interim 23 Mar 2018
    07 Sep 2017 $0.0000 100.00% Final 28 Sep 2017
    08 Sep 2016 $0.0150 0.00% Final 29 Sep 2016
    10 Mar 2016 $0.0150 0.00% Interim 24 Mar 2016
    15 Mar 2006 $0.0050 100.00% Special 05 Apr 2006
    15 Mar 2006 $0.0200 100.00% Interim 05 Apr 2006
    14 Sep 2005 $0.0050 100.00% Special Cash 04 Oct 2005
    14 Sep 2005 $0.0275 100.00% Final 04 Oct 2005
    16 Mar 2004 $0.0125 100.00% Interim 05 Apr 2004

    PME ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Pro Medicus Ltd

    Pro Medicus Ltd (ASX: PME) is a provider of medical imaging technology globally. The company is recognised as a leading supplier of radiology information systems (RIS), picture archiving and communication systems (PACS), and advanced visualisation solutions for medical practices and hospitals.

    Pro Medicus's RIS technology products also include medical accounting, clinical reporting, appointments/scheduling, and marketing/management applications. The company's services to the imaging sector cover workflow mapping and optimisation, network design and implementation, hardware sourcing and configuration, and staff and management training.

    Pro Medicus has offices in Australia, Germany, and the US with its products adopted by many top-tier hospitals and health facilities, particularly in the US market.

    PME Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    26 Feb 2026 $127.60 $11.37 9.78% 795,477 $120.10 $127.67 $120.10
    25 Feb 2026 $116.23 $8.08 7.47% 601,935 $109.91 $116.23 $108.60
    24 Feb 2026 $108.15 $-7.15 -6.20% 783,400 $111.99 $114.34 $107.75
    23 Feb 2026 $115.30 $-11.21 -8.86% 517,235 $127.08 $127.58 $115.30
    20 Feb 2026 $126.51 $-2.65 -2.05% 510,902 $128.88 $129.49 $123.36
    19 Feb 2026 $129.16 $6.16 5.01% 653,806 $124.64 $129.78 $121.51
    18 Feb 2026 $123.00 $-2.96 -2.35% 758,014 $125.50 $130.00 $122.21
    17 Feb 2026 $125.96 $8.99 7.69% 757,291 $117.42 $127.55 $116.98
    16 Feb 2026 $116.97 $-1.25 -1.06% 769,492 $118.30 $121.32 $113.67
    13 Feb 2026 $118.22 $-10.78 -8.36% 1,455,798 $126.95 $128.90 $118.22
    12 Feb 2026 $129.00 $-40.47 -23.88% 1,129,492 $152.48 $152.48 $129.00
    11 Feb 2026 $169.47 $1.81 1.08% 283,625 $165.00 $169.56 $163.50
    10 Feb 2026 $167.66 $6.49 4.03% 200,701 $163.00 $167.66 $161.79
    09 Feb 2026 $161.17 $3.55 2.25% 482,202 $162.00 $162.90 $159.30
    06 Feb 2026 $157.62 $-7.31 -4.43% 325,920 $161.60 $162.07 $155.63
    05 Feb 2026 $164.93 $-1.42 -0.85% 399,506 $166.35 $168.48 $163.39
    04 Feb 2026 $166.35 $-11.21 -6.31% 471,636 $167.88 $170.00 $162.19
    03 Feb 2026 $177.56 $-0.59 -0.33% 265,894 $178.15 $179.26 $175.39
    02 Feb 2026 $178.15 $-5.97 -3.24% 264,631 $182.00 $182.00 $175.48
    30 Jan 2026 $184.12 $2.43 1.34% 313,605 $181.27 $185.13 $178.84
    29 Jan 2026 $181.69 $-4.59 -2.46% 371,211 $187.08 $187.27 $178.61
    28 Jan 2026 $186.28 $-3.89 -2.05% 320,367 $194.00 $194.85 $184.32

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    26 Feb 2026 Anthony Hall Buy 8,146 $993,812
    On-market trade.
    25 Feb 2026 Anthony Hall Buy 9,000 $1,029,690
    On-market trade.
    24 Feb 2026 Sam Hupert Buy 4,500 $489,240
    On-market trade.
    24 Feb 2026 Anthony Hall Buy 8,500 $936,105
    On-market trade.
    23 Feb 2026 Peter Kempen Buy 400 $46,572
    On-market trade.
    13 Feb 2026 Deena Shiff Buy 788 $99,815
    On-market trade.
    13 Feb 2026 Anthony Glenning Buy 2,080 $249,204
    On-market trade.
    29 Dec 2025 Peter Kempen Buy 600 $134,400
    On-market trade. As per announcement - 30/12/2025
    23 Dec 2025 Sam Hupert Buy 2,250 $499,477
    On-market trade.
    23 Dec 2025 Anthony Hall Buy 2,270 $500,103
    On-market trade.
    22 Dec 2025 Sam Hupert Buy 2,250 $498,262
    On-market trade.
    22 Dec 2025 Anthony Hall Buy 2,250 $499,275
    On-market trade.
    03 Sep 2025 Sam Hupert Transfer 50,000 $14,950,000
    Off-market transfer. Estimated value
    12 Mar 2025 Anthony Glenning Buy 50 $10,979
    On-market trade.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Dr Sam Aaron Hupert Chief Executive OfficerManaging Director Oct 2007
    Mr Hupert, left general practice in late 1984 to devote himself full time to managing the Group. Sam served as CEO from the time he co-founded the company until October 2007 at which time he stepped down to become an executive director. Sam resumed full time CEO activities in October of 2010.
    Mr Anthony Barry Hall Executive DirectorTechnology Director Jan 1983
    Mr Hall has been principal architect and developer of the core software systems that underpin Visage RIS.
    Mr Peter Terence Kempen Non-Executive ChairmanNon-Executive Director Mar 2008
    Mr Kempen is Chairman of Australasian Leukemia and Lymphoma Group. He is also a Trustee of the Barr Family Foundation and a member of the Boards of St Hilda's College Ltd, University of Melbourne, and the Olivia Newton-John Cancer Research Institute. Peter has previously been Chairman of Patties Food Limited, Chairman of Danks Holdings Limited, Chairman of Ivanhoe Grammar School and Managing Partner of Ernst & Young Corporate Finance Australia. Peter was appointed a Member in the General Division of the Order of Australia (AM) in the 2018 Queen's Birthday Honors. He became Chairman in August 2010 before which he served as a Non-Executive Director of the Company.
    Ms Alice Joan Morrice Williams Non-Executive Director Sep 2021
    Ms Williams is also a non-executive director of Vocus Group, Swimming Australia, Australian Submarine Corporation (ASC Pty Ltd) and Mercer Investments Australia Ltd. She is chair of the Audit & Risk Committee of ASC and Vocus Group and is a member of the Audit & Risk Committee and Due Diligence Committee of Mercer Investments (Australia) Ltd. Alice holds other board positions with Tobacco Free Portfolios and is on the Advisory Council of the Florey Institute of Neuroscience Novell Project. Previous board roles include Director and Chair of the Audit Committee of Cooper Energy, Djerriwarrh Investments, Chair of Nomination, Remuneration and Human Resources Committee and Non-Executive Director of Equity Trustees Ltd, and Nonexecutive member of the Foreign Investment Review Board. Alice is Chair of the Risk committee and serves on the People & Culture committee.
    Ms Deena Robyn Shiff Non-Executive Director Aug 2020
    Ms Shiff is an Independent Board Member of the Global Alliance for Vaccines and Immunization, the multi-lateral global health fund based in Geneva, the Chairman of AROSE (Australian Remote Operations in Space and Earth), and since July 2025, the Chairman of the Australian Telecommunications Alliance. and Chairman of the Care Economy Co Operative Research Centre. She also chairs the International Advisory Board of the Australian Research Centre of Excellence on Automated Decision Making and Society. Deena is Chair of the People & Culture committee and serves on the Risk committee.
    Mr Anthony James Glenning Non-Executive Director May 2016
    Mr Glenning is a fund adviser to Skalata Ventures, investing in early-stage companies to help them scale and grow into sustainable businesses. Anthony has previously been an Investment Director at Starfish Ventures and was the founder and CEO of Tonic Systems and a founding Non-Executive Director of Cameron Systems. He has also held senior software engineering positions at Google and Sun Microsystems Inc. Anthony also serves on the People & Culture committee and Risk committee.
    Dr Leigh Bernard Farrell Non-Executive Director Sep 2017
    Dr Farrell is the Managing Director of AdNED Pty Ltd, non-executive director of both Ena Respiratory Pty Ltd and Axelia Oncology Pty Ltd, a member of the Walter and Eliza Hall Institute of Medical Research Board Commercialization Committee, a member of the Scientific and Industry Advisory Committee of the Australian Research Council Centre for Cryo-electron Microscopy of Membrane Proteins and a member of the Investment Committee for the CUREAtor Plus.Dementia and Cognitive Decline Grants which is funded by the Australian Medical Research Future Fund. Leigh was previously Head of Health Security Systems Australia, a Division of DMTC Ltd, Senior Vice President, Commercial of Certara USA, Inc. where he was responsible for Asia Pacific Commercial. Prior to this, he was Chairman and COO of d3 Medicine LLC, which was acquired by Certara USA, Inc. Leigh also serves on the People & Culture committee and Risk committee.
    Ms Danny English Company Secretary Mar 2023
    -
    Clayton Hatch Chief Financial Officer
    -
    Danny English Company Secretary
    -
    Malte Westerhoff General Manager Europe and Global Chief Technology Officer
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Mr A Hall (multiple shareholdings) 24,144,000 23.11%
    Dr S Hupert (multiple shareholdings) 24,137,660 23.11%
    HSBC Custody Nominees (Australia) Limited 23,739,921 22.73%
    J P Morgan Nominees Australia Limited 7,952,739 7.61%
    Citicorp Nominees Pty Ltd 7,726,022 7.40%
    BNP Paribas Noms Pty Ltd 1,781,046 1.70%
    Mr Peter Terence Kempen & Mrs Elaine Margaret Kempen multiple shareholdings) 629,082 0.60%
    Mr Michael Wu 439,242 0.42%
    Grain Exporters (Australia) Pty Ltd 437,925 0.42%
    National Nominees Limited 402,482 0.39%
    Netwealth Investments Limited 297,897 0.29%
    Mr Stephen Geoffrey Wilson & Ms Denise Adele Prandi 281,417 0.27%
    Mr Colin Gregory Organ 271,000 0.26%
    Mr John Charles Plummer 250,000 0.24%
    Mr Danny Tauber 164,007 0.16%
    Mr Bram Vander Jagt & Mrs Maaike Vander Jagt 140,000 0.13%
    Mr Sean Michael Lambright 127,587 0.12%
    A Haig Retirement Manager Pty Ltd 114,723 0.11%
    Mr Kenneth John Vander Jagt & Mrs Tanya Vander Jagt 103,000 0.10%
    BNP Paribas Noms (Nz) Ltd 90,680 0.09%

    Profile

    since

    Note